Don’t miss Terry Arnold, PA-C, MBA, and Vice President of DermTech’s Medical Affairs team speak about living with intent and opportunities for Physician Assistants in industry. Listen here: podcasts.apple.com/gb/podcas…

DermTech is proud to support the Association of Military Dermatologists. If you missed us at the 2024 meeting, message us to learn more about TRICARE and VA coverage for the DermTech Melanoma Test.

New clinical study data presented at Winter Clinical: The Trust 2 Study included follow-up evaluations on 2-GEP performance from 5,096 lesions with biopsy results or confirmed clinical follow up. dermtech.com/wp-content/uplo…

New article from @DermTimesNow : Maral Kibarian Skelsey, MD, discusses the real-world implications of the new study's findings for dermatology clinicians. Full interview here: dermatologytimes.com/view/ma…

Check out our latest poster, “Non-invasive gene expression analysis rules out melanoma with high negative predictive value regardless of skin phototype” presented at the Winter Clinical Dermatology Conference (January 12-17, 2024). dermtech.com/wp-content/uplo…

“This is significant progress toward making this test available for patients with Fitzpatrick skin types IV-VI, which is important because ruling out melanoma in individuals with these skin types can be particularly challenging.” businesswire.com/news/home/2…

"With an NPV that remains at 99% or higher, the DMT provides genomic information for a suspicious pigmented lesion that a clinician may be hesitant to biopsy for various reasons." businesswire.com/news/home/2…

“The Trust 2 Study illustrates that a high NPV test such as the DMT can allow physicians to confidently rule out melanoma for their patients,” commented Maral K. Skelsey, M.D., one of the lead Trust 2 Study investigators." bit.ly/41YsYEV

Headed to Winter Clinical 2024 in Hawaii? Send us a message to meet with our Medical Affairs team and learn more about the real-world utility of the DermTech Melanoma Test and our new Trust 2 Study data. We look forward to seeing you there! #WCH24

“The Trust 2 Study results reaffirm the DMT’s real-world clinical utility to rule out melanoma with a negative predictive value (NPV) that is higher than other currently available methods,” said Loren Clarke, M.D., chief medical officer, DermTech.  investors.dermtech.com/news-…